San Francisco, 01 February 2024: The Report Real-time PCR, Digital PCR, And End-point PCR Market Size, Share & Trends Analysis Report By Technology (Quantitative, Digital, End-point), By Product, By Application, By Region, And Segment Forecasts, 2024 - 2030

The global real-time PCR, digital PCR, and end-point PCR market size is expected to reach USD 7.18 billion by 2030, registering a CAGR of 4.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. However, the real global real-time PCR, digital PCR, and end-point PCR market without the impact of the COVID-19 pandemic is expected to expand at a compound annual growth rate (CAGR) of 8.7% from 2023 to 2030. Digital PCR is a novel technique for absolute quantification and analysis of minority sequences in the presence of similar majority sequences. dPCR allows for precise and sensitive nucleic acid measurement. In addition, real-time PCR provides precise and early diagnosis of diseases and rapid and targeted patient care hence anticipated to increase the demand in the coming years

The rise in the occurrence of diseases such as lung cancer, blood cancer, and brain tumors is fueling the application expansion of the global market. According to Globocan 2020, lung cancer is the second most common cancer in Europe, with an estimated 477,534 newly diagnosed cases. Furthermore, the benefits of digital polymerase chain reaction over traditional technologies such as real-time and quantitative polymerase chain reaction are likely to drive adoption throughout the forecast period. Moreover, rising healthcare expenditures in emerging nations and the increased need for accurate molecular disease detection are propelling the market growth.

Furthermore, the COVID-19 pandemic has increased the demand for digital PCR instruments and reagents. COVID-19 infections are detected using modern digital PCR instruments as a molecular diagnosis technique. According to the WHO, around 273 million cases have been diagnosed and roughly 5.3 million deaths have been documented worldwide due to COVID-19 as of December 2021. Moreover, in the pharmaceutical industry, digital PCR machines are also employed in R&D.

Furthermore, advancements in technology and an increase in the number of product launches in the global market are expected to support the market growth. For instance, in June 2021, Bio-Rad Laboratories, Inc. announced the release of the PREvalence ddPCR SARS-CoV-2 waste-water quantifying kit for COVID-19 wastewater screening.

Additionally, the increase in R&D projects for advancements in technology and an increase in collaborations between firms for the development of digital polymerase chain reactions are expected to increase the usage of PCR testing. For instance, Qiagen partnered with Atila BioSystems & Actome GmbH in January 2022 to deliver non-invasive prenatal testing (NIPT) technologies to QIAGEN's dPCR for a growing number of applications for QIAcuity. As a result, the usage of real-time and digital PCR technologies is projected to increase during the forecast period.

Request sample report of Real-time PCR, Digital PCR, And End-point PCR Market@ https://www.grandviewresearch.com/industry-analysis/real-time-pcr-qpcr-digital-pcr-dpcr-market/request/rs1

Furthermore, rapid detection of infectious diseases with the use of polymerase chain reaction facilitates timely intervention and can enable the delivery of appropriate treatments. For instance, slow detection of tuberculosis through traditional methods can be overcome by utilizing polymerase chain reaction, which provides faster and more efficient results. Thus, an increase in prevalence of chronic diseases is expected to create growth opportunities for the market.

Real-time PCR, Digital PCR, And End-point PCR Market Report Highlights

• By technology, the Quantitative PCR segment held largest revenue share of over 83.34% in 2023. This is attributed to the high adoption of technology supported by the introduction of products based on real-time polymerase chain reaction for screening and diagnosis of COVID-19
• The consumables and reagents segment held the largest revenue share of over 62.62% in 2023 due to the increased demand for earlier detection and the number of significant companies manufacturing digital PCR consumables and reagents
• North America dominated the market with a revenue share of over 35.94% in 2023 due to the presence of high R&D investment, the availability of a technologically advanced healthcare research framework, the strong presence of prominent polymerase chain reaction manufacturers, and an expanding requirement for rapid diagnostic tests in the region

The adoption of PCR techniques is increasing owing to their accuracy, automation, precision, real-time quantification, and sensitivity. For instance, in May 2023, the state government of Orissa, India, decided to expand the NAT-PCR testing facility to all blood centers in a comprehensive manner rather than in phases. This expansion was estimated to cost approximately Rs 200 crore (USD 24.3 Million). This decision came in response to two PILs urging the introduction of NAT-PCR facility in all blood banks in India due to its ability to detect HIV-1, HIV-2, hepatitis B, and hepatitis C at an earlier stage compared to the traditional ELISA test.

The market is also characterized by a medium level of merger and acquisition (M&A) activity by the leading players. In February 2023, Thermo Fisher Scientific, Inc. partnered with Mylab, a leading biotech company in India, to design and development of RT-PCR kits. Companies are adopting these strategies to increase their expertise and gain access to new regions in the emerging market.

The market is subject to increasing regulatory scrutiny. The regulatory framework for diagnostic product approvals is one of the major factors restraining the market growth. Moreover, the U.S. FDA plans to regulate laboratory-developed tests (LDTs) under medical device regulations, which is further anticipated to restrain the market uptake after implementing new rules.

Presence of substitute technologies such as immunoassay and other molecular diagnostic techniques can hamper the market uptake of PCR-based products. The increasing introduction of novel immunoassay tests, NGS, and others are becoming core substitutes for polymerase chain reactions. Moreover, the cost-effectiveness and increasing accuracy of immunoassay coupled with rapid test results make it a suitable substitute for the market.

Real-time PCR, Digital PCR, And End-point PCR Market Report Scope

End-user concentration is a major factor in the market. Increasing penetration of novel and portable PCR devices in hospitals, physician offices, central laboratories, POC facilities, and others is driving the market. Moreover, increasing demand for rapid and POC tests for oncology, biological markers, genetic tests for inherited conditions, and others is increasing demand for PCR tests.

Standard BioTools, Stilla, Sensible Diagnostics, BGI Genomics, Virax Biolabs Group Limited, and others are emerging market participants in the real-time PCR, digital PCR, and end-point PCR market. Mid-level companies are developing novel tests and collaborating with overseas players to increase their global market footprint by offering innovative diagnostic solutions for difficult-to-detect diseases.

List Of Key Players Real-time PCR, Digital PCR, And End-point PCR Market

• Abbott
• Qiagen
• Bio-Rad Laboratories Inc.
• Agilent Technologies, Inc.
• Thermo Fisher Scientific, Inc.
• GE Healthcare
• bioMérieux
• F. Hoffmann-La Roche Ltd
• Fluidigm Corporation